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Abstract
Background
A major cause of disability in secondary progressive multiple sclerosis (SPMS)
is progressive brain atrophy, whose pathogenesis is not fully understood. The
objective of this study was to identify protein biomarkers of brain atrophy in
SPMS.
 
Methods
We used surface-enhanced laser desorption-ionization time-of-flight mass
spectrometry to carry out an unbiased search for serum proteins whose
concentration correlated with the rate of brain atrophy, measured by serial MRI
scans over a 2-year period in a well-characterized cohort of 140 patients with
SPMS.  Protein species were identified by liquid chromatography-electrospray
ionization tandem mass spectrometry.
 
Results
There was a significant (p<0.004) correlation between the rate of brain atrophy
and a rise in the concentration of proteins at 15.1 kDa and 15.9 kDa in the
serum.  Tandem mass spectrometry identified these proteins as
alpha-haemoglobin and beta-haemoglobin, respectively.  The abnormal
concentration of free serum haemoglobin was confirmed by ELISA (p<0.001). 
The serum lactate dehydrogenase activity was also highly significantly raised
(p<10 ) in patients with secondary progressive multiple sclerosis. 
 
Conclusions
An underlying low-grade chronic intravascular haemolysis is a potential source
of the iron whose deposition along blood vessels in multiple sclerosis plaques
contributes to the neurodegeneration and consequent brain atrophy seen in
progressive disease. Chelators of free serum iron will be ineffective in
preventing this neurodegeneration, because the iron (Fe ) is chelated by
haemoglobin.
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Introduction
In multiple sclerosis (MS), progressive disease develops in over half 
of those who present with an initial relapsing phase – secondary 
progressive MS (SPMS) – but can also present as primary pro-
gressive MS (PPMS). Progressive MS, for which there is no clear 
disease-modifying treatment1–3, accounts for much of the disability 
and the cost of MS to both the person and the community4.
Unlike relapsing-remitting MS (RRMS), where an inflammatory 
response involving the adaptive immune system leads to episodic 
neurological deficits, in progressive MS neuroaxonal loss leads to 
an increasing neurological deficit and brain atrophy5,6. However, in 
all forms of the disease, both the initiating events and the mecha-
nisms of pathogenesis remain uncertain5. Pseudoatrophy may 
account for some loss of brain volume7, but brain atrophy has also 
been associated with changes in neurofilament levels8 and sodium 
metabolism9.
The objective of the present study was to use an unbiased, 
high-throughput technique to identify protein biomarkers of 
brain atrophy in a longitudinal cohort of patients with SPMS. We 
used surface-enhanced laser desorption-ionization time-of-flight 
(SELDI-TOF) mass spectrometry to analyse serial serum samples 
from the population that participated in the MS-STAT study 
(described below)1, to identify proteins whose abundance was 
associated with MRI-measured brain atrophy rate. Serum 
proteomics in MS has previously been investigated in small 
cross-sectional studies to compare relapsing MS and progres-
sive disease10–12. However, these previous studies were neither 
designed nor powered to identify correlates of neurodegeneration in 
SPMS.
We found that the rate of brain atrophy in this cohort was associ-
ated with an increase in the concentration of free haemoglobin in 
the serum. This association was independent of the beneficial effect 
of simvastatin treatment, which remained significant in the present 
analysis. An ELISA assay confirmed the presence of abnormal 
concentrations of free haemoglobin in the serum of patients with 
SPMS. In addition, the serum lactate dehydrogenase (LDH) activity 
was significantly greater in patients with SPMS than in three differ-
ent groups of control subjects. These results suggest that chronic 
intravascular haemolysis releases haemoglobin into the serum in 
SPMS; we postulate that this haemoglobin is a source of the abnor-
mal iron deposition along blood vessels in the central nervous sys-
tem that is associated with neurodegeneration in progressive MS.
Methods
Ethical approval
The study was done in accordance with Good Clinical Practice 
and the Declaration of Helsinki. The protocol was approved by the 
UK National Research Ethics Service (Berkshire Research Ethics 
Committee; reference 07/Q1602/73), and every patient gave written 
informed consent before entering the study.
Subjects
The MS-STAT clinical trial was registered with ClinicalTrials.gov 
(NCT00647348) and has been described in detail elsewhere1. In 
this phase 2 placebo-controlled double-blind trial, 140 patients with 
SPMS were randomized 1:1 to simvastatin 80 mg/day (40 mg for 
the first month) or matched placebo. The patients were in trial for 
2 years. The primary outcome was change in whole brain volume as 
measured by the Brain Boundary Shift Integral (BBSI), with MRI 
data acquired at baseline, 12 months and 25 months; the last MRI 
scan (25 months) was carried out 1 month after last medication 
to minimize any potential artefactual changes in volume1. Simv-
astatin treatment resulted in a highly statistically significant 43% 
reduction in the annualized rate of brain atrophy1, and significant 
changes were also seen in certain clinician- and patient-reported 
outcome measures. As control groups in the haemoglobin assays, 
we studied healthy adult volunteers (n=20); patients with human 
T-lymphotropic virus (HTLV-1)-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP), which closely resembles chronic 
spinal forms of multiple sclerosis (n=20); and asymptomatic 
HTLV-1 carriers (n=20).
Protein profiling of serum by SELDI-TOF mass spectrometry
SELDI-TOF mass spectrometry was performed on 475 serum 
samples collected at baseline, 6 month, 12 months and 24 
months. Samples were randomized, and staff were blinded to the 
treatment arms. CM10 ProteinChip arrays (Bio-Rad Laboratories) 
were primed with binding buffer (50 mM ammonium acetate, 
 0.01% Triton X-100, pH 4·0) and incubated at room temperature 
(RT) for 5 min. A 1:10 dilution of serum in binding buffer was 
then applied to the array and incubated at RT for 1 hr. The arrays 
were washed twice with binding buffer and deionized water. 
Saturated sinapinic acid (0.7 µL) was applied twice to each spot 
on the arrays. Time-of-flight spectra were generated using a 
PCS-4000 mass spectrometer (Bio-Rad). Low-range spectra (mass/
charge (m/z) ratio 0 – 20,000) were obtained at a laser energy of 
3000 nJ, with a focus mass of 6000 and the matrix attenuated to 
1000. High-range spectra (m/z 10,000 – 75,000) were obtained at 
a laser energy of 3900 nJ, with a focus mass of 30,000 and the 
matrix attenuated to 10,000. Mass accuracy was calibrated exter-
nally using All-in-One Peptide or Protein molecular mass standards 
(Bio-Rad).
Proteomics data processing
Spectra were analysed using ProteinChip Data Manager (Bio-Rad 
version 4.1.0) and normalized using total ion current. Peaks were 
auto-detected using a peak threshold of 12.5% and a mass window 
of 0.3%, and the resulting data were converted for subsequent 
analysis using R software. The abundance (intensity) of a given 
protein peak was quantified as the area under the peak; peak 
intensities were log-transformed before analysis. After exclusion of 
one contaminated sample and 4 technical failures, the proteomics 
data consisted of 470 spectra from 138 patients.
Protein enrichment and identification
Ten µL serum were applied to Top 12 Abundant Protein Depletion 
Spin Columns (Thermo Scientific Pierce) according to the manu-
facturer’s protocol. Five hundred µL of the eluate were concentrated 
on a 3 kDa molecular weight cut-off column (Amicon) in 25 mM 
Tris-HCl, pH 8.0. Twenty µL of depleted serum were separated 
by 1D SDS-PAGE on an 18% Tris-glycine denaturing gel (TGX, 
Bio-Rad) at 150 V for 70 min and compared against SeeBlue 
Plus 2 pre-stained protein standard (Life Technologies). The gel 
was rinsed 5 times with deionized water and stained overnight in 
See Band staining solution (Gene Bio-Application Ltd.) A band 
Page 3 of 10
Wellcome Open Research 2016, null:null Last updated: 26 OCT 2016
corresponding to 15 to 16 kDa was excised and an in-gel trypsin 
digest13 was carried out.
Samples were analysed by nanoscale liquid chromatography- 
electrospray ionization tandem mass spectrometry (LC-MS/MS), 
using a nanoAcquity UPLC system (Waters MS Technologies, 
Manchester, UK). Peptide identification was performed using 
ProteinLynx Global SERVER v3.1 (Waters). 
Serum haemoglobin concentration
Free haemoglobin levels were assayed by ELISA (Abcam 
ab157707) according to the manufacturer’s protocol. Samples 
were analysed in random order, and staff were blinded to the treat-
ment arms. Absorbance was measured at 450 nm on a SpectraMax 
microplate reader (Molecular Devices).
Serum lactate dehydrogenase (LDH) activity
Serum LDH activity was assayed by the conversion of lactate to 
pyruvate, using the absorption of light at 340 nm by the reaction 
product NADH (Abbott Laboratories, ref. 7D69).
Statistics
All statistical models were carried out using R software14. To test 
for associations between SELDI-TOF mass spectrometry peak 
intensity changes and treatment group, linear regression models 
were fitted separately for each spectral peak at each follow-up time 
(6, 12 and 24 months), modelling log(peak intensity change from 
baseline) as a function of baseline log(peak intensity), treatment 
group, and the five randomization variables (age, gender, EDSS 
[Expanded Disability Severity Scale], neuroscience centre, and 
assessing physician).
To test for associations between peak intensity changes and brain 
volume changes, for each pair of time points (0–12 months, 
0–25 months and 12–25 months) the BBSI was compared with 
the change in each peak intensity. Linear regression was used to 
model the log(change in peak intensity) as a function of BBSI 
(expressed as a percentage of baseline whole-brain volume), 
adjusted for baseline log(peak intensity), MRI centre, and the five 
randomization variables.
For both treatment and brain volume analyses, sensitivity analysis 
was carried out using repeated-measures models including all 
four time points. Protein peaks whose regression coefficients 
differed significantly from zero (Wald test) were selected for 
further analysis. To take into account multiple testing, the p-value 
foreach peak was converted into the False Discovery Rate (FDR: 
expected proportion of false positives) for that p-value threshold, 
using the R package fdrtool15. Peaks at FDR ≤ 0.2 were retained for 
further analysis.
The results of the haemoglobin ELISA and the serum LDH assay 
were analysed using two-tailed Mann-Whitney tests to test for 
pairwise differences between the subject groups.
Results
Intensity of specific protein peaks was associated with 
change in brain volume
Expression-difference mapping of all longitudinal serum samples 
(peak threshold of 12.5%; mass window of 0.3% minimum) 
resulted in detection of 145 peaks that were differentially expressed 
within individual subjects over time.
To determine whether changes in protein levels (SELDI-TOF 
peak intensity) were associated with simvastatin treatment, we ran 
regression models for the change in each protein peak intensity vs. 
treatment status, adjusting for the 5 randomization variables and 
MRI centre. No association remained significant after adjusting for 
multiple comparisons (the lowest level at which the FDR could be 
controlled was 0.3).
We next ran regression models for change in protein intensity 
v. brain volume loss, for each interval in which the BBSI was 
measured (0 to 12 months; 12 to 25 months) and over the whole 
trial period (0 to 25 months). The changes in intensity of peaks 
at m/z = 25,110 and 25,402 were significantly associated with the 
change in brain volume between baseline and 12 months (p=0.001, 
corresponding to FDR = 0.08). The regression coefficients for the 
association were negative, i.e. an increase in these protein intensi-
ties was associated with a smaller decrease in brain volume. The 
change in intensity of the peaks at m/z = 15,141 and 15,885 between 
baseline and 25 months was significant in each case (p=0.003 and 
0.001 respectively), corresponding to a FDR of 0.2. For these 
peaks the regression coefficients were positive, i.e. an increase in 
these peaks was associated with a larger decrease in brain volume 
(Figure 1). There were no significant regression coefficients 
for the 12 to 25 month time period. Repeated-measures models 
for the whole time period of the trial also identified the peaks at 
m/z = 15,141 and 15,885 as significant at an FDR of 0.2.
Multiple regression analysis, modelling brain volume change as 
a function of protein peak intensity, treatment status, and the five 
randomization variables and MRI centre as covariates confirmed 
(Table 1) that simvastatin treatment and the protein peak intensity 
were independently associated with the rate of brain atrophy.
The multiple regression model (Table 1) explained 25% of the 
observed variation in the rate of brain atrophy over the two-year 
observation period; the protein peak at 15.1 kDa alone explained 
10% of this variation. The regression coefficient of -0.6 for 
simvastatin treatment indicates a mean difference in brain atrophy 
rate between treatment groups of -0.6% over the 2-year trial period; 
this estimate (-0.3%/year) is consistent with the rate of -0.25%/year 
previously reported in the MS-STAT trial1. The regression coeffi-
cient of 0.75 for BBSI v. protein change means that two patients 
whose protein increases differ by 30% have an expected difference 
in brain atrophy rate of 0.1% over two years (the patient with higher 
increase in protein 15.1kDa expects a greater decrease in brain 
volume).
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Figure 1. Change in intensity of 15.1 kDa peak correlated with rate of brain atrophy. Normalized log(change in intensity of 15.1 kDa peak 
between baseline and 2-year follow-up) versus percentage decrease in brain volume between baseline and 2 years. Solid line shows the 
best fit from the linear regression model (regression coefficient = 0.12, p=0·001). Protein ratios were normalized to all other covariates, using 
the linear regression model. Crosses represent treated individuals, circles represent untreated individuals. The correlation with the 15.9 kDa 
peak was closely similar (regression coefficient = 0.12, p=0·001).
Table 1. Multiple linear regression analysis of the association 
between change in brain volume and change in the peak intensity of 
the proteins whose changes were found to be significantly correlated 
with change in brain volume. Beta = regression coefficient. The model is 
adjusted for the 5 randomization variables and MRI centre.
m/z 15885 (0 to 25 months) m/z 15141 (0 to 25 months)
Beta (95% CI) p Beta (95% CI) p
protein 0.83 (0.33, 1.33) 0.001 0.75 (0.29, 1.22) 0.002
treatment -0·62 (-1.06, -0.19) 0.005 -0.60 (-1.03, -0.17) 0.007
m/z 25110 (0 to 12 months) m/z 25402 (0 to 12 months)
Beta (95% CI) p Beta (95% CI) p
protein -0.99 (-1.72, -0.26) 0.008 -0.73 (-1.37, -0.09) 0.025
treatment -0.26 (-0.56, -0.04) 0.090 -0.27 (-0.58, -0.04) 0.083
Identification of proteins associated with brain atrophy
After enrichment, the intensity of the protein peaks at 25.1 kDa 
and 25.4 kDa remained insufficient to allow their isolation and 
identification. However, the peaks at 15.1 kDa and 15.9 kDa 
remained at high intensities and distinct from nearby peaks 
(Figure 2). LC-MS/MS identified twenty-six peptide fragments 
matching human proteins: 15 fragments corresponded to human 
α-haemoglobin and the remaining 11 fragments corresponded to 
β-haemoglobin (Table 2; Supplementary Table 1). Of the remaining 
364 sequence matches (after exclusion of bacterial sequences and 
the common contaminant keratin), the top 360 were partial matches 
to haemoglobin subunits of other mammalian species.
ELISA confirms the presence of free serum haemoglobin in 
MS patients
We assayed free haemoglobin by ELISA in MS patients (n=20) 
and in three control groups (n=20 in each group; Materials and 
Methods). The results (Figure 3A) showed significantly higher 
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Figure 2. SELDI-TOF mass spectrometry spectra of 15.1 kDa and 15.9 kDa peaks. (A.) Following enrichment on Top 12 Protein Depletion 
column and (B.) Concentration of eluate on 3 kDa molecular weight cutoff column.
Table 2. Identification of peptide fragments from 15.1 kDa and 15.9 kDa protein peaks, 
using LC-MS/MS. *oxidation of M(1). **oxidation of M(15).
Peak m/z Protein name Accession no. 
(UniProt)
PLGS 
score
Peptide matches
1 15,141 Haemoglobin  
alpha
P69905 2049 (R)VDPVNFK(L)  
(R)MFLSFPTTK(T)*  
(K)VGGHAAEYGAEALER(M) 
(R)MFLSFPTTK(T)
2 15,885 Haemoglobin  
beta
P68871 2579 (R)FFESFGDLSTPDAVMGNPK(V)** 
(R)LLVVYPWTQR(F)  
(K)EFTPPVQAAYQK(V)  
(R)FFESFGDLSTPDAVMGNPK(V)  
(K)LHVDPENFR(L)
concentrations of free haemoglobin in the serum from MS 
patients, when compared to each control group (p<0.001 in each 
comparison; Mann-Whitney). Of the 20 MS patients assayed, 17 
had a serum haemoglobin concentration greater than the mean 
+ 2 standard errors of the healthy adult controls. No significant 
difference was observed between the three control groups.
Abnormally high serum LDH activity in MS patients
The presence of free haemoglobin in the serum in MS patients 
suggested a degree of intravascular haemolysis in these individu-
als. To seek corroborative evidence of haemolysis, we assayed 
the serum LDH activity. The median LDH activity in the patients 
with MS was significantly greater than that in each of the three 
control groups (Figure 3B; p<10-12 in each case; Mann-Whitney); 
no significant difference was found between the three con-
trol groups, in each of which the LDH was within the normal 
range.
The mean erythrocyte count, haematocrit and total blood hae-
moglobin in the cohort were within the normal range (see Data 
availability), and there was no association between these 
parameters and the rate of brain atrophy.
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AB
Figure 3. Free serum haemoglobin and lactate dehydrogenase are raised in secondary progressive multiple sclerosis. A. Serum 
haemoglobin concentration measured by ELISA in asymptomatic carriers of HTLV-1 (AC), patients with HTLV-1-associated myelopathy (HAM), 
uninfected, healthy controls (HC), and patients with secondary progressive MS. Log [haemoglobin] by ELISA was significantly correlated with 
log(peak intensity): r = 0.52; p = 0.02; linear regression. B. Serum lactate dehydrogenase (LDH) activity in the same groups of subjects.
Discussion
The characteristic pathological feature of early, active multiple 
sclerosis lesions is primary demyelination, with partial preserva-
tion of axons. But the dominant feature in progressive disease is 
neurodegeneration, which results in brain atrophy. Factors asso-
ciated with this neurodegeneration5 include microglial activation, 
chronic oxidative injury, mitochondrial damage in axons, and iron 
accumulation. A strong correlate of neurodegeneration in MS is 
abnormal iron deposition in both grey and white matter in MS, 
especially along veins and venules in cerebral MS plaques16,17. 
Iron can potentiate oxidative damage by generating hydroxyl radi-
cals by the Fenton reaction. The extent of iron accumulation, as 
indicated by T2 signal hypointensity on MRI, is correlated 
with disease progression, lesion accumulation and cell death of 
oligodendrocytes18–20. The extent of iron deposition is greater in 
SPMS than in relapsing-remitting disease18.
The source of this abnormal iron deposited in the central nerv-
ous system in MS is unknown. Iron is liberated from damaged 
oligodendrocytes and myelin21 and accumulates in macrophages 
and microglia at the margin of active lesions, but it remains unclear 
whether this is the principal source of the iron that accumulates 
in the vessel walls and perivascular space. Bamm and Harauz22 
proposed that chronic extravasation of red blood cells is a source 
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of the abnormal iron deposits; however, neuropathological evi-
dence does not show frequent or widespread extravascular erythro-
cytes in the MS brain.
The results presented here show that a rise in the concentration 
of free haemoglobin in the serum was associated with the rate of 
brain atrophy in this cohort of patients with SPMS. This effect was 
independent of the beneficial treatment effect of simvastatin, 
because there was no association between free haemoglobin con-
centration and simvastatin treatment. Since a successful response 
to simvastatin treatment was not associated with the free serum 
haemoglobin concentration, we infer that the change in free serum 
haemoglobin was not a consequence of brain atrophy but preceded 
brain atrophy in the causal pathway.
These results suggest the hypothesis that chronic, low-grade 
intravascular haemolysis releases haemoglobin into the serum, 
which is then translocated into the CNS parenchyma across the 
impaired blood-brain barrier and potentiates oxidative damage to 
oligodendrocytes. Cytotoxicity by free haemoglobin can be medi-
ated by intact haemoglobin itself, by haem, or by iron, especially 
as Fe2+22. Free haemoglobin is degraded by haem oxygenase-1 
(HO-1), producing biliverdin and Fe2+ ions. HO-1 is upregulated 
in glia by oxidative stress, and HO-1 is expressed in oligodendro-
cytes in actively demyelinating areas in MS, but not in two other 
CNS diseases, human acute disseminated leukoencephalomyeli-
tis (ADEM) or murine experimental allergic encephalomyelitis 
(EAE)23. Stahnke et al.23 proposed that the role of stress-induced 
HO-1 is protective initially, whereas chronic upregulation might 
cause oligodendrocyte death.
The observation (Figure 3B) of abnormally high serum LDH 
activity is consistent with the presence of haemolysis in these 
patients. LDH is present in all cell types, and serum LDH is raised 
in many inflammatory conditions; however, erythrocytes are par-
ticularly rich in LDH, and serum LDH is a sensitive marker of 
haemolysis. The notion that chronic intravascular haemolysis might 
serve as a source of the iron deposited in MS is also consistent 
with earlier reports of abnormal fragility of erythrocytes. Erythro-
cytes from patients with MS, especially those with active disease, 
are abnormally susceptible to lysis by both mechanical stress24 and 
osmotic stress25. The causes of this erythrocyte fragility remain to 
be identified. Possible artefactual causes of haemolysis, such as 
venepuncture, cannot explain the significant association observed 
here between brain atrophy and free serum haemoglobin.
If intravascular haemolysis indeed occurs in SPMS, the rate of 
red cell destruction is insufficient to reduce the total blood hae-
moglobin, which remained within normal limits in this cohort. 
Neurodegeneration is not a feature of other chronic haemolytic 
conditions, such as spherocytosis or elliptocytosis; however, in 
these conditions the blood-brain barrier is intact, and most erythro-
cyte destruction occurs in the spleen, where efficient phagocytosis 
may prevent the release of the toxic breakdown products into the 
circulation.
Polymorphisms in genes encoding iron-binding and iron-trans-
porting proteins are associated with disability, disease severity 
and early progression in MS26. Rithidech et al.27 used 2D elec-
trophoresis to identify plasma biomarkers in paediatric MS: the 
haem-bindingprotein haemopexin was 1 of 12 proteins found to be 
upregulated in 9 MS patients. Robotti et al.28 identified an alteration 
in the ratio of isoforms of haptoglobin (which bind free haemo-
globin) in MS.
These results do not suggest that free serum haemoglobin 
concentration is useful in the differential diagnosis of neurological 
disease; rather, they identify a potential contributor to the patho-
genesis of neurodegeneration in progressive multiple sclerosis.
Previous studies of serum iron have shown normal concentrations 
in the serum in patients with MS29; however, standard assays of 
free serum iron do not detect iron that is sequestered in haemo-
globin. Iron chelation has been proposed as a therapy to approach to 
reduce neurodegeneration in MS. However, if an important source 
of iron is free serum haemoglobin, standard iron-chelating agents 
such as desferrioxamine will be ineffective, again because the iron 
is sequestered in haemoglobin30. Scavengers of haemoglobin and 
haemin31 might be more effective.
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